274 related articles for article (PubMed ID: 16582060)
1. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.
Kendrick T; Peveler R; Longworth L; Baldwin D; Moore M; Chatwin J; Thornett A; Goddard J; Campbell M; Smith H; Buxton M; Thompson C
Br J Psychiatry; 2006 Apr; 188():337-45. PubMed ID: 16582060
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
[TBL] [Abstract][Full Text] [Related]
3. Are SSRIs a cost-effective alternative to tricyclics?
Hotopf M; Lewis G; Normand C
Br J Psychiatry; 1996 Apr; 168(4):404-9. PubMed ID: 8730935
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatment of depression with and without headache disorders: an appraisal of cost effectiveness and cost utility of antidepressants.
Pan YJ; Kuo KH; Wang SJ
J Affect Disord; 2015 Jan; 170():255-65. PubMed ID: 25261631
[TBL] [Abstract][Full Text] [Related]
5. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
6. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
[TBL] [Abstract][Full Text] [Related]
7. Does the use of SSRIs reduce medical care utilization and expenditures?
Chung S
J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
[TBL] [Abstract][Full Text] [Related]
8. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
Machado M; Iskedjian M; Ruiz IA; Einarson TR
Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis.
Arroll B; Macgillivray S; Ogston S; Reid I; Sullivan F; Williams B; Crombie I
Ann Fam Med; 2005; 3(5):449-56. PubMed ID: 16189062
[TBL] [Abstract][Full Text] [Related]
10. Meta-analytical studies on new antidepressants.
Anderson IM
Br Med Bull; 2001; 57():161-78. PubMed ID: 11719915
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
[TBL] [Abstract][Full Text] [Related]
12. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis.
von Wolff A; Hölzel LP; Westphal A; Härter M; Kriston L
J Affect Disord; 2013 Jan; 144(1-2):7-15. PubMed ID: 22963896
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit analysis of newer versus older antidepressants--pharmacoeconomic studies comparing SSRIs/SNRIs with tricyclic antidepressants.
Laux G
Pharmacopsychiatry; 2001 Jan; 34(1):1-5. PubMed ID: 11229615
[TBL] [Abstract][Full Text] [Related]
14. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability.
Anderson IM
Depress Anxiety; 1998; 7 Suppl 1():11-7. PubMed ID: 9597346
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
Lenox-Smith A; Conway P; Knight C
Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability.
Qin B; Zhang Y; Zhou X; Cheng P; Liu Y; Chen J; Fu Y; Luo Q; Xie P
Clin Ther; 2014 Jul; 36(7):1087-1095.e4. PubMed ID: 24998011
[TBL] [Abstract][Full Text] [Related]
17. TCAs or SSRIs as initial therapy for depression?
Tyra JM; Greenawald MH
J Fam Pract; 1999 Nov; 48(11):845-6. PubMed ID: 10907616
[No Abstract] [Full Text] [Related]
18. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression.
Crown WH
Acta Psychiatr Scand Suppl; 2000; 403():62-6. PubMed ID: 11019937
[TBL] [Abstract][Full Text] [Related]
19. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
20. Depression and pain: an appraisal of cost effectiveness and cost utility of antidepressants.
Pan YJ; Pan CH; Chan HY; Kuo KH
J Psychiatr Res; 2015 Apr; 63():123-31. PubMed ID: 25727051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
